Actively Recruiting
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Led by Shandong New Time Pharmaceutical Co., LTD · Updated on 2025-12-31
90
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.
CONDITIONS
Official Title
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma according to the IMWG 2016 criteria
- Previous treatment must include lenalidomide used continuously for at least 2 cycles and a proteasome inhibitor
- No prior treatment with pomalidomide or intolerance to pomalidomide
- ECOG performance status score between 0 and 2
- Have at least one measurable disease indicator: serum M-protein 5 5 g/L, urine M-protein 5 200 mg/24 h, or involved serum free light chain level 5 100 mg/L with abnormal ratio
You will not qualify if you...
- Presence of primary light-chain amyloidosis or plasma cell leukemia
- Symptoms of central nervous system involvement of multiple myeloma
- History of other malignancies within 3 years before the first dose (except multiple myeloma)
- Active mucosal or visceral bleeding
- Previous treatment with BCMA-targeted therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Actively Recruiting
Research Team
L
Lu gui Qiu Doctor
CONTACT
S
Shaohong Yin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here